Evidence map›Paper›PMID 30886123›Full record

ArticleMolecular and cellular biology2019

Targeted Degradation of Glucose Transporters Protects against Arsenic Toxicity.

Marco Jochem, Lukas Ende, Marta Isasa, Jessie Ang, Helena Schnell, Angel Guerra-Moreno, Yagmur Micoogullari, Meera Bhanu, Steven P Gygi, John Hanna

Open access · bronzeAbstract read
In one paragraph

Article in Molecular and cellular biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. The Dsc complex and its role in Golgi quality control.Biochemical Society transactions · 2024
    Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Marco JochemDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Lukas EndeDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Marta IsasaDepartment of Cell Biology, Harvard Medical School, Boston, Massachusetts, USA.
Jessie AngDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Helena SchnellDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Angel Guerra-MorenoDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Yagmur MicoogullariDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Meera BhanuDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Steven P GygiDepartment of Cell Biology, Harvard Medical School, Boston, Massachusetts, USA.
John HannaDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA jwhanna@bwh.harvard.edu.
Harvard University · USBrigham and Women's Hospital · US

Funding

New Sample Multiplexing Technologies to Identify Chemical Probes and Illuminate Ubiquitin BiologyR01GM067945 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI GYGI, STEVEN P · 2003 to 2024
$10.5M
New Ubiquitin-Proteasome System Components that Protect against ProteotoxicityDP5OD019800 · OD · BRIGHAM AND WOMEN'S HOSPITAL · PI HANNA, JOHN W · 2014 to 2018
$2.2M
NIGMS NIH HHS R01 GM067945NIH HHS DP5 OD019800
6 · The paper itself

Abstract

The abundance of cell surface glucose transporters must be precisely regulated to ensure optimal growth under constantly changing environmental conditions. We recently conducted a proteomic analysis of the cellular response to trivalent arsenic, a ubiquitous environmental toxin and carcinogen. A surprising finding was that a subset of glucose transporters was among the most downregulated proteins in the cell upon arsenic exposure. Here we show that this downregulation reflects targeted arsenic-dependent degradation of glucose transporters. Degradation occurs in the vacuole and requires the E2 ubiquitin ligase Ubc4, the E3 ubiquitin ligase Rsp5, and K63-linked ubiquitin chains. We used quantitative proteomic approaches to determine the ubiquitinated proteome after arsenic exposure, which helped us to identify the ubiquitination sites within these glucose transporters. A mutant lacking all seven major glucose transporters was highly resistant to arsenic, and expression of a degradation-resistant transporter restored arsenic sensitivity to this strain, suggesting that this pathway represents a protective cellular response. Previous work suggests that glucose transporters are major mediators of arsenic import, providing a potential rationale for this pathway. These results may have implications for the epidemiologic association between arsenic exposure and diabetes.

Indexed as

ArsenicDown-RegulationGlucose Transport Proteins, FacilitativeMicrobial ViabilityMutationProteolysisProteomicsSaccharomyces cerevisiaeUbiquitinationArsenicGlucose Transport Proteins, Facilitativearsenicglucose transporterprotein degradationRsp5ubiquitin

Identifiers

PMID30886123
PMCPMC6497993
OpenAlexW2921338296

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.